SIRIUS Trial: Diameter Restenosis

Slides:

Advertisements

Similar presentations

ENDEAVOR IV Acronym: ENDEAVOR IV. Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics,

Advertisements

Challenges from Drug Eluting Stent (DES) Studies - Future DES Study Design Peter S. Lam, Ph.D. Director, Biostatistics, Medical Sciences.

Www. Clinical trial results.org The C-SIRIUS Study A The Canadian Multi-Center, Randomized, Double-Blind Study of the Sirolimus-Eluting Stent in the Treatment.

“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:

Www. Clinical trial results.org The RAVEL Study A RAndomised (double blind) study with the Sirolimus coated BX™ VElocity balloon expandable stent (CYPHER™)

Four Drug Eluting Stent Trials Keith D Dawkins MD FRCP FACC Southampton University Hospital Keith D Dawkins MD FRCP FACC Southampton University Hospital.

Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.

The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®

NOBORI New Generation Drug Eluting Stent Clinical Data Danny Detiege Clinical Manager - Cardiology Terumo Europe N.V. Leuven, Belgium.

Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.

SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.

FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary.

Slow-rate release polymer-based paclitaxel- eluting stent compared with bare stent in patients with single complex coronary lesions TAXUS V Presented at.

A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.

Direct Stenting is Better (Debate Session) 동아의대 김 무 현.

Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.

Www. Clinical trial results.org Cypher sirolimus-eluting stent Primary Endpoint:  In-stent and late lumen loss at 9 months (determined by QCA) Secondary.

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.

TLR Funnel plot (according to outcomes) for studies included in the meta-analysis Death A TVR B MACE DC SE(log OR)

End points in PTCA trials. A successful angioplasty is defined as the reduction of a minimum stenosis diameter to

Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.

Intravascular ultrasound (IVUS) in percutaneous coronary intervention – summary of key articles While angiography is routinely used for assessment of CAD,

Disclosures Runlin Gao has received a research grant

Ospedale San Raffaele, Milan, Italy

Runlin Gao, M.D. On behalf of ABSORB China Investigators

on behalf of the ABSORB II Investigators

From: Paclitaxel-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal StentsThe TAXUS V ISR Randomized Trial JAMA. 2006;295(11):

TAXUS II: Slow Release Formula An International, Randomized, Multicenter, Blinded Trial of TAXUSTM NIRxTM SR Stent Presented at TCT 2002.

(DES)+BVS +DCB for long diffuse LAD disease

Volume 54, Issue 1, Pages (August 2009)

ABSORB Japan: 3-year Clinical and Angiographic Results of a Randomized trial Evaluating the Absorb Bioresorbable Vascular Scaffold vs. Metallic Drug-eluting.

LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.

TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.

Stent Thrombosis Rates in Contemporary Clinical Practice: Insight from a Large Australian Multi-centre Registry BP Yan*, TJ Kiernan, SJ Duffy, DJ Clark,

on behalf of the ABSORB II Investigators

On behalf of J. Belardi, M. Leon, L. Mauri,

DESolve® SERIES OF CLINICAL STUDIES

The Biofreedom Surface Etching Polymer-Free DES System

on behalf of the ABSORB II Investigators

Stenting of Coronary Arteries in Non Stress/Benestent Disease

Impact of calcium on procedural and clinical outcomes in lesions treated with bioresorbable vascular scaffolds - A prospective BRS registry study Jiang.

TAXUS II and IV: two-year follow-up

Long-term follow-up of the DIABETES I (DIABETes and sirolimus Eluting Stent) trial: P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín,

American College of Cardiology Presented by Dr. Stephan Windecker

TAXUS II: Moderate Release Formula An International, Randomized, Multicenter, Blinded Trial of TAXUSTM NIRxTM MR Stent Presented at TCT 2002.

REALITY: 8 month results

EXCITE ISR Trial design: Participants with femoropopliteal in-stent restenosis were randomized to excimer laser atherectomy + adjunctive angioplasty (n.

Kyoto University Hospital, Japan

3-Year Clinical Outcomes From the RESOLUTE US Study

ENDEAVOR IV: 5 Year Final Outcomes

Presented at ACC 2003 Late Breaking Clinical Trials

The American College of Cardiology Presented by Dr. Raimund Erbel

Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.

SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.

Main branch restenosis at 1 year

Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.

(a) Dyslipidaemia (b) Final MLD P = P = P = 0.972

ENDEAVOR II Five-Year Clinical Follow-up

FOR DISTRIBUTION BY MEDTRONIC OFFICE OF MEDICAL AFFAIRS ONLY.

ENDEAVOR III Multicenter Randomized Trial Clinical/MACE Angio/IVUS

Updated 3-Year Meta-Analysis of the TAXUS Clinical Trials Safety and Efficacy Demonstrated in 3,445 Randomized Patients Time allocation for this talk.

Presented at TCT 2006.

Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J

Maintenance of Long-Term Clinical Benefit with

TAXUS VI Randomized Trial of Moderate-Rate Release Polymer-Based Paclitaxel-Eluting TAXUS Stent for the Treatment of Longer Lesions Three Year Clinical.

Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: First Report of the Five-Year Clinical Outcomes from.

MACE: Death, MI or TLR at 5 years

Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial

The American College of Cardiology Presented by Dr. A. Abazid

TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.

Presentation transcript:

SIRIUS Trial: Diameter Restenosis P<0.001 P=0.001 % Proximal Segment % Distal Segment % In Segment % In stent P=NS P=0.14 Coated Bare Coated Bare Coated Bare Coated Bare Peristent Restenosis (PSR): 5 mm proximal and distal to the stent In stent Restenosis (ISR): within the margins of the stent In Segment: Sum of PSR and ISR Euro PCR 2002

SIRIUS Trial: Late Loss (mm) P=0.14 P=0.009 P=0.001 P<0.001 Distal Segment In Segment Proximal Segment In stent Coated Bare Coated Bare Coated Bare Coated Bare Peristent Restenosis (PSR): 5 mm proximal and distal to the stent In stent Restenosis (ISR): within the margins of the stent In Segment: Sum of PSR and ISR Euro PCR 2002

SIRIUS Trial: Minimum Lumen Diameter at Follow-Up (mm) In stent MLD (mm) In stent MLD (mm) In stent MLD (mm) Coated Bare Coated Bare Coated Bare Small Vessels: Median 2.30 Medium Vessels: Median 2.79 Large Vessels: Median 3.00 Euro PCR 2002

SIRIUS Trial: In Stent Restenosis at Follow-Up (%) Coated Bare Coated Bare Coated Bare Small Vessels: Median 2.30 Medium Vessels: Median 2.79 Large Vessels: Median 3.00 Euro PCR 2002

SIRIUS Trial: In Segment Restenosis at Follow-Up (%) Coated Bare Coated Bare Coated Bare Small Vessels: Median 2.30 Medium Vessels: Median 2.79 Large Vessels: Median 3.00 Euro PCR 2002

SIRIUS Trial: Lesion Length and IVUS Findings Plaque Volume NIH IVUS Volume Restenotic Lesion Length (mm) Coated Bare Coated Bare Coated Bare Euro PCR 2002

SIRIUS: Loss Index (Late Loss / Acute Gain) In Stent In Segment Loss Index Euro PCR 2002

Target Lesion Revasc (TLR) Target Vessel Failure (TVF) SIRIUS: TLR and TVF Target Lesion Revasc (TLR) Target Vessel Failure (TVF) P<0.001 P<0.001 Incidence (%) Euro PCR 2002

SIRIUS: Clinical Events Stent Thrombosis < 24 hrs Incidence (%) Coated Bare Coated Bare Coated Bare Coated Bare Coated Bare Coated Bare Stent Thrombosis < 24 hrs Stent Thrombosis Day 1 - 30 Death Q wave MI Non Q wave MI MACE Euro PCR 2002